<div id=”js-article__body” itemprop=”articleBody” data-sbid=”WP-MKTW-0000222156″>
There is a link between the AstraZeneca AZN vaccine, -0.24% AZN, -0.21% COVID-19 and rare blood clots, according to a senior official at the European Medicines Agency. “In my opinion, we can say it now, it is clear that there is a link with the vaccine. But we still don’t know what causes this reaction, ”Marco Cavaleri, EMA’s director of vaccines, told the Italian newspaper Il Messaggero in an interview published on Tuesday.
He added that “in the next few hours we will say that there is a connection, but we still have to understand how this happens.” “We are trying to get an accurate picture of what is happening, to define in detail this syndrome due to the vaccine,” Cavaleri said, adding: “Among those vaccinated, there are more cases of cerebral thrombosis… among young people than us. assume. “The comments come as broadcaster Channel 4 reported that the UK’s health
regulator, the Medicines and Health Products
Regulatory Agency (MHRA), is considering a proposal to restrict the use of the AstraZeneca vaccine in people. younger people, due to concerns about very rare blood clots. Two high-level sources said that “while the data is still unclear, there are growing arguments to justify offering younger people, at least under 30 years of age , a different vaccine, “Channel 4 News reported. Later Monday, MHRA Executive Director Dr. June Raine said no decision had been made on any action and urged people to continue getting vaccinated.” Our comprehensive and detailed review is ongoing on the reports of very rare and specific types of blood clots with low platelets after the COVID-19
AstraZeneca vaccine, “Raine said. made a decision on no regulatory action, “he added. Read: EU regulator declares AstraZeneca vaccine ‘safe’ after blood clot investigation Most European Union countries restarted use of AstraZeneca vaccine late last month, after EMA conclude that the injection is the overall risk of blood clots. “However, some countries, including France and Germany, have limited use of the vaccine to people under 60 years of age. Read: Canada suspends AstraZeneca vaccine for adults 55 and older years or less The EMA said at the time that it could not yet “definitively rule out” a link between the blood clot reports and the vaccine, and said its Pharmacovigilance Risk Assessment Committee would continue to study the links. The PRAC will meet. this week to discuss the latest testing, after which a further announcement is expected. AstraZeneca has said its own review of the safety data of more than 17 million people Vaccinated ones in the UK and EU showed no evidence of an increased risk of blood clots. Shares of AstraZeneca, which fell more than 2.35% so far this year, according to FactSet data, fell 0.29% in London trading